This is a working overview of lyophilised powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
A defensive reaction of the skin is the formation of a light callus, the skin's own sun protection, which corresponds to a protection factor of about 5. At the same time, the production of brown skin pigments (melanin) in the corresponding cells (melanocytes) is stimulated. A solar control film is usually a film made of polyethylene terephthalate (PET) that is applied to windows to reduce the light and heat from the sun's rays. The film filters UV-A and UV-B radiation. Polyethylene terephthalate goes back to an invention by the two Englishmen John Rex Whinfield (1902-1966) and James Tennant Dickson in 1941.
== Ecology == In nature, A. roeperi is found primarily on the walls of ambrosia beetle galleries within a wide variety of host trees, where it survives by degrading compounds within wood. Traditionally, although they facilitate beetle growth and reproduction in nutritionally poor xylem tissue, ambrosia fungi are considered to be ineffective agents of wood decomposition, producing enzymes primarily dedicated to degradation of xylan, glucomannan, and callose (common components of hemicellulose) rather than cellulose, mirroring similar analyses made for various saprotrophic fungi. However, no equivalent studies have been performed on A. roeperi specifically, and it is worth noting that the article often cited in support of this conclusion only examined the fungal galleries of one beetle (Xyleborinus saxenii) associated with a different symbiont, Raffaelea sulfurea. Interestingly, metabolomic studies incorporating A. roeperi indicate that when growing on wood, this fungus possesses a lipid profile more similar to non-mutualistic Ceratocystidaceae than to other ambrosia fungi, further supporting the idea that making sweeping conclusions about fungal lifestyles based on data from apparently similar convergent systems can be misleading, as well as reinforcing how much remains to be learned about this and other ambrosial species. There are various molecular indications that hint at other ways in which A. roeperi may interact with its woody hosts.
== Structure == Prolidases fall under a subclass of metallopeptidases that involve binuclear active site metal clusters. This metal cluster facilitates catalysis by serving as a substrate binding site, activating nucleophiles, and stabilizing the transition state. Furthermore, prolidases are classified under a smaller family called "pita-bread" enzymes, which cleave amido-, imido-, and amidino- containing bonds. The "pita-bread" fold, containing a metal center flanked by two well-defined substrate binding pockets enabled prolidase to specifically cleave between any non-proline amino acid and proline.
== Viscoelasticity == Viscoelasticity is the phenomena of time-dependent strain exhibited by amorphous materials such as polymers or glasses. The viscoelasticity of materials depend on the viscosity and can be mechanically modelled using mechanical elements known as springs and dashpots. In turn, constitutive equations can relate the mechanical interpretation of viscoelasticity to the materials properties and strain rate.
Collagen sponges: Collagen sponges are used as a dressing to treat burn victims and other serious wounds. Collagen based implants are used for cultured skin cells or drug carriers that are used for burn wounds and replacing skin. Collagen as haemostat: When collagen interacts with platelets it causes a rapid coagulation of blood. This rapid coagulation produces a temporary framework so the fibrous stroma can be regenerated by host cells. Collagen based haemostat reduces blood loss in tissues and helps manage bleeding in organs such as the liver and spleen. Chitosan is another popular biopolymer in biomedical research. Chitosan is derived from chitin, the main component in the exoskeleton of crustaceans and insects and the second most abundant biopolymer in the world. Chitosan has many excellent characteristics for biomedical science. Chitosan is biocompatible, it is highly bioactive, meaning it stimulates a beneficial response from the body, it can biodegrade which can eliminate a second surgery in implant applications, can form gels and films, and is selectively permeable. These properties allow for various biomedical applications of chitosan. Chitosan as drug delivery: Chitosan is used mainly with drug targeting because it has potential to improve drug absorption and stability. In addition, chitosan conjugated with anticancer agents can also produce better anticancer effects by causing gradual release of free drug into cancerous tissue. Chitosan as an anti-microbial agent: Chitosan is used to stop the growth of microorganisms.
Sources: en.wikipedia.org
=== Sjögren's disease === Sjögren's disease is a long-term autoimmune disease that affects the body's moisture-producing glands (lacrimal and salivary), and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.
James Rowley French (September 23, 1928 – December 20, 2017) was an American radio host, voice actor, writer and producer. French founded Imagination Theatre in 1996 and served as its producer until 2017. He was the morning DJ on the Seattle radio station KIRO from 1959 to 1971, and again from 1980 to 1994. As a voice actor, French was known for his work in video games by Valve, including Half-Life 2 (2004), Left 4 Dead (2008), and Dota 2 (2013).
On 3 March, US and Israeli strikes destroyed the SNSC headquarters, the Expediency Discernment Council building in Tehran, and what Israeli officials described as an alleged underground nuclear weapons facility called Min Zadai. The proximity of these strikes to the Bushehr Nuclear Power Plant (about 12 km (7.5 mi) away) prompted the Russian agency Rosatom to suspend construction on new units and evacuate non-essential staff. A CIA site in the US embassy in Riyadh was hit by Iranian drones. US officials said its forces had severely damaged Iran's naval capabilities, mainly in the Gulf of Oman, where several Iranian warships were destroyed and key bases hit. Debris from an airstrike damaged Golestan Palace, a UNESCO World Heritage Site, causing UNESCO to issue a statement that damaging UNESCO sites is against international law. Israel Katz authorized a ground invasion of Lebanon on 3 March with forces from the 91st Division, with the stated goal to establish a "security layer" against Hezbollah. The Lebanese government reported that Israeli attacks reached Kfarkela and Qouzah, leading the Lebanese army to redeploy from newly established border posts. Israel reported that it killed Daoud Alizadeh, the commander of the Quds Force's Lebanon branch, in Tehran. Western diplomats said Qatar had struck Iran after Iran had attempted to strike Doha's airport and Qatar shot down two Iranian Su-24 bombers. Qatar denied the accusation that it had joined the "campaign targeting Iran".
Rocha-Méndez et al. (2026) report evidence from the study of mitochondrial genomes of European fallow deers from the Neumark-Nord sites (Germany) indicative of loss of genetic diversity of the species since the Pleistocene, recovering the studied extinct population from a single Eemian locality with as much genetic diversity as seen in extant population with a Eurasian range. Chung & Cho (2026) describe new antler remains of Elaphurus formosanus from the Pleistocene of Taiwan and support recognition of the species as distinct. Amanova, Drucker & Fontana (2026) reconstruct the ecology and habitat use of red deers from the Epigravettian sequence of Riparo Tagliente (Italy) on the basis of the study of carbon and oxygen isotopic composition of their tooth enamel, reporting evidence of a diet based on C3 plants and life in the landscape dominated by open woodland environments. Kubo, Yamazaki & Taniguchi (2026) reconstruct the diet of early to mid-Holocene sika deers from the Iyai Rockshelter Site (Japan) on the basis of the study on their tooth wear texture, reporting evidence of abrasive food in their diets and short-term temporal changes in foraging conditions. Martínez-Polanco (2026) determines diet of extant Neotropical deer (including local dietary variation within species) on the basis of the study of their tooth wear, providing reference data that can be used to determine diets of fossil deer and other small- to medium-sized ungulates.
== Gland atrophy == The adrenal glands atrophy during prolonged use of exogenous glucocorticoids like prednisone. Atrophy of the breasts can occur with prolonged estrogen reduction, as with anorexia nervosa or menopause. Testicular atrophy can occur with prolonged use of enough exogenous sex steroids (either androgen or estrogen) to reduce gonadotropin secretion.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.